MED17

MED17 (Srb4/TRAP80) is a head-module subunit of the Mediator complex that is essential for RNA Polymerase II transcription, structurally bridging the head and middle domains and serving as a hub for preinitiation complex assembly (PMID:9710620, PMID:16962561). The temperature-sensitive srb4-138 allele dissociates Mediator at the head/middle boundary and causes loss of the head domain from active promoters, producing a global shutdown of Pol II transcription that establishes MED17 as architecturally indispensable to the complex (PMID:16962561). Human MED17 directly contacts Pol II and the general transcription factors TFIIB, TBP, TFIIE, and TFIIH and supports transcriptional activation, and it also engages histone H4 tails within Mediator (PMID:22693636, PMID:25482373). Beyond core transcription, MED17 connects to nucleotide excision repair: it binds the TFIIH helicase subunit XPB and the endonuclease XPG, and after UV-C irradiation colocalizes with these NER factors and associates with p53 (PMID:25482373). MED17 is a selective coactivator whose target specificity is tuned by signal-dependent phosphorylation: CK2 phosphorylates Ser53 in response to insulin to drive lipogenic gene transcription through a direct interaction with USF1 at the FASN promoter, p38 MAPK phosphorylation at Thr570 gates this CK2 event, and MARK2 phosphorylates Ser152 to selectively enhance NF-κB (RelA) target transcription (PMID:28223413, PMID:33596087). In the liver, MED17 selectively promotes LXR-dependent transcription of SREBP-1c but not ABCA1, controlling Pol II recruitment to specific LXREs and modulating steatosis and triglyceride metabolism in vivo (PMID:25437875). Missense mutation of MED17 (p.L371P) inactivates the protein in a yeast complementation test (PMID:20950787).

1. 1998 High

   Established that Med17/Srb4 functions cooperatively with another Mediator subunit (Med6) as part of a defined subcomplex required for Pol II activation, placing it within the Mediator architecture rather than as an isolated factor.

   Evidence Allele-specific genetic suppressor screen plus biochemical Mediator subcomplex co-purification in yeast

   PMID:9710620

   Open questions at the time

   • Did not resolve the structural basis of the Med6-Srb4 interaction
   • Did not define which activators depend on this interaction
2. 2006 High

   Resolved why MED17 is essential by showing it holds the head and middle modules together, with loss of the head domain from promoters explaining the global cessation of Pol II transcription.

   Evidence Biochemical purification of Mediator from srb4-138 mutant yeast plus ChIP at permissive and non-permissive temperatures

   PMID:16962561

   Open questions at the time

   • Did not provide atomic-resolution structure of the head/middle interface
   • Mechanism of head retention at active promoters not detailed
3. 2010 Medium

   Linked human MED17 dysfunction to disease by demonstrating that a patient missense mutation abolishes the conserved protein function.

   Evidence Yeast complementation assay with the homologous SRB4 mutation

   PMID:20950787

   Open questions at the time

   • Functional consequence tested only by surrogate yeast complementation, not in human cells
   • No mechanistic dissection of how the mutation alters Mediator function
4. 2012 Medium

   Identified a direct contact between MED17 and histone H4 tails, suggesting how Mediator may read chromatin in the vicinity of promoters.

   Evidence UV photo-crosslinking with crosslinker-substituted histone tail peptides and yeast-purified Mediator

   PMID:22693636

   Open questions at the time

   • In vitro crosslinking only; functional consequence of the H4 contact untested
   • No reciprocal or in-cell validation
5. 2014 Medium

   Mapped human MED17's direct partners (Pol II, TFIIB, TBP, TFIIE, TFIIH) and revealed an unexpected role linking Mediator to nucleotide excision repair via XPB/XPG and p53 after UV damage.

   Evidence Pulldown and in vitro binding assays, luciferase reporters in knockdown cells, and immunofluorescence colocalization after UV-C irradiation

   PMID:25482373

   Open questions at the time

   • NER role inferred from colocalization, not from direct repair assays
   • Single lab without reciprocal validation of all interactions
6. 2014 High

   Demonstrated promoter-selective coactivation, showing MED17 distinguishes between LXR targets (SREBP-1c vs ABCA1) and thereby separates lipogenesis from reverse cholesterol transport in vivo.

   Evidence shRNA and adenoviral liver-specific knockdown, ChIP for Pol II at LXREs, and in vivo metabolic phenotyping in mice

   PMID:25437875

   Open questions at the time

   • Molecular basis for promoter discrimination between SREBP-1c and ABCA1 not defined
   • Did not identify the MED17 region mediating LXRE selectivity
7. 2017 High

   Established signal-dependent control of MED17 by showing CK2 phosphorylation at Ser53 (gated by p38 phosphorylation at Thr570) couples insulin signaling to lipogenic transcription through a direct USF1 interaction.

   Evidence In vitro CK2 kinase assay with S53A mutagenesis, Co-IP of MED17-USF1, and knockdown/overexpression in hepatocytes and mouse liver

   PMID:28223413

   Open questions at the time

   • Structural effect of Ser53 phosphorylation on Mediator not resolved
   • Cross-talk logic between p38 and CK2 events only partially defined
8. 2021 High

   Extended the phospho-regulation model by showing MARK2 phosphorylation of MED17 at Ser152 selectively tunes NF-κB target transcription, establishing MED17 as a node integrating polarity-kinase signaling with inflammatory gene programs.

   Evidence In vitro phosphorylation with recombinant MARK2, phosphomimetic/null mutagenesis, Co-IP with RelA, and transcriptome analysis

   PMID:33596087

   Open questions at the time

   • Mechanism by which Ser152 phosphorylation selects specific NF-κB transcripts not defined
   • Physiological context of MARK2-MED17 signaling untested in vivo
9. 2021 Low

   Connected MED17 deficiency to a cellular stress phenotype by showing patient-mutant fibroblasts exhibit elevated unfolded protein responses.

   Evidence RT-qPCR for CHOP/ATF4 and immunoblot for p-eIF2α in patient-derived fibroblasts

   PMID:34392449

   Open questions at the time

   • No mechanistic link established between MED17 mutation and UPR activation
   • Single lab, descriptive biochemistry without rescue

• How MED17's multiple phosphorylation events and partner contacts are integrated to achieve gene-selective coactivation, and the structural basis for its promoter discrimination, remain unresolved.
• No structural model linking phospho-sites to Mediator conformation
• Mechanism of promoter/target selectivity uncharacterized
• Causal chain from human mutations to cellular phenotypes incomplete